- Home
- BIAF vs IMRN Comparison
BIAF vs IMRN Comparison
Compare BIAF & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- IMRN
- Stock Information
- Founded
- BIAF 2014
- IMRN 1994
- Country
- BIAF United States
- IMRN Australia
- Employees
- BIAF N/A
- IMRN N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- IMRN Health Care
- Exchange
- BIAF Nasdaq
- IMRN Nasdaq
- Market Cap
- BIAF 12.2M
- IMRN 10.3M
- IPO Year
- BIAF 2022
- IMRN N/A
- Fundamental
- Price
- BIAF $0.21
- IMRN $1.55
- Analyst Decision
- BIAF Hold
- IMRN Strong Buy
- Analyst Count
- BIAF 1
- IMRN 1
- Target Price
- BIAF N/A
- IMRN $5.00
- AVG Volume (30 Days)
- BIAF 799.6K
- IMRN 15.0K
- Earning Date
- BIAF 05-23-2025
- IMRN 05-27-2025
- Dividend Yield
- BIAF N/A
- IMRN N/A
- EPS Growth
- BIAF N/A
- IMRN N/A
- EPS
- BIAF N/A
- IMRN N/A
- Revenue
- BIAF $9,362,022.00
- IMRN $4,048,286.00
- Revenue This Year
- BIAF N/A
- IMRN N/A
- Revenue Next Year
- BIAF $19.99
- IMRN N/A
- P/E Ratio
- BIAF N/A
- IMRN N/A
- Revenue Growth
- BIAF 269.68
- IMRN 82.90
- 52 Week Low
- BIAF $0.16
- IMRN $1.60
- 52 Week High
- BIAF $2.99
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- BIAF 32.86
- IMRN 44.57
- Support Level
- BIAF $0.19
- IMRN $1.87
- Resistance Level
- BIAF $0.24
- IMRN $2.13
- Average True Range (ATR)
- BIAF 0.04
- IMRN 0.13
- MACD
- BIAF -0.02
- IMRN -0.00
- Stochastic Oscillator
- BIAF 13.80
- IMRN 7.50
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.